Merck (MRK) Options Activity Points to Bullish Momentum—Here’s How to Play the Breakout

• Strong Q1 results and a $4.2B acquisition on deck
• Call open interest surges past puts at key strikes
• Price above 30D MA but still below 200D MA — long-term trend intact
• Today’s 1.06% gain hints at growing confidence

Merck is showing signs of a breakout. Call open interest is up sharply at key strike levels, and the stock is trading comfortably above its 30-day moving average. With strong earnings, a major acquisition, and a robust buyback program in motion, the market is clearly pricing in optimism. But options data also reveals pockets of risk — especially around the $120 level. Let’s break down the numbers to find where the real money is moving.

Decoding the Options Imbalance and Strike-Level Pressure

Merck’s options market is leaning heavily into the call side — the put/call ratio for open interest is 0.718, meaning calls are dominating the conversation. That’s not always a buy signal, but when you layer in where the money is being placed, it tells a clearer story.

The most striking numbers come from the next Friday expiry (April 17). At $130, the call strike has a staggering 19,443 contracts open — more than all other next-week call strikes combined. That suggests a significant number of traders are pricing in a potential $130+ move. The $125 call has the second-largest open interest at 11,308, and the $122 call isn’t far behind at 4,139. This isn’t random — these strikes represent key psychological and technical levels.

On the put side, the largest open interest is at $105 (4,532), followed by $95 (3,822) and $110 (3,713). That shows some hedging activity but nothing that screams “big move down.” For now, the market isn’t pricing in a deep correction.

No major block trades were reported today, which is normal for Merck’s volume, but the concentration of open interest at $130 is still telling. If you’re a big player, you don’t open 19,000 contracts unless you see a target in sight.

Company News: Fueling the Bull Case, Not Just Noise

Merck’s Q1 beat and $4.2B acquisition of BioXPharma are more than just headlines — they’re catalysts. The acquisition adds three late-stage oncology candidates, including a Phase III lung cancer drug, which could drive revenue in 2027. That’s a solid foundation for a longer-term bull case.

The buyback program and dividend increase are also boosting shareholder confidence. Analysts are already factoring in a mid-single-digit EPS boost from these moves. And with a new CFO in place and a $6.5B R&D investment announced, Merck is showing it’s willing to bet big on its future.

That said, investors should stay cautious. Merck’s stock has yet to break above the 200-day moving average ($96.80), which is a long-term support zone. A breakout above $122.17 (Bollinger Upper Band) could signal a shift from a consolidation phase to a momentum phase.

Actionable Trading Setups: Stocks and Options

If you’re bullish on Merck, the next few weeks are prime time to act. Here’s how to structure the trade:

For a long stock entry, consider buying Merck around $120.50 — just below today’s high — with a stop-loss just below the 30D MA at $115.74. If the stock holds there, the first target is the 200D MA at $117.46, with the next major level at $122.17 (Bollinger Upper Band). If it breaks that, watch for a run toward $125.

For options players, the most attractive setup is the MRK20260417C125 call. With 11,308 contracts in open interest, this is a strike that’s already seeing action. Buy this call at a reasonable premium (wait for a pullback to $120.55 or lower), and you’ll get leverage if Merck pushes above $125 before expiration. If you prefer a lower-risk play, the MRK20260410C122 call (483 OI) could work, especially if you’re bullish on short-term news like the new diabetes drug launch.

Bearish investors could look at the MRK20260417P110 put at 3,713 OI. If Merck pulls back below the 30D MA and struggles to hold key levels, this could be a way to hedge or bet on a short-term dip. But keep in mind — the RSI is still in neutral territory (62.25), so a sharp drop isn’t priced in.

Volatility on the Horizon — Position Now, Pay Later

Merck is at an inflection point. The stock is sitting on a short-term high and a long-term low — a classic setup for a breakout. With earnings momentum, an aggressive buyback, and a new R&D push, the fundamentals are aligned for a push higher. Options data confirms it: money is moving into strike levels that imply a 10% move from current price to $130.

The risks are clear — the stock still has to hold its current trend above $115.74. But if it does, the path to $125 is open. And in options, that means opportunity. Whether you go long the stock or take a call position, now is the time to act before the market catches up.